Table 1 Comparison between the wet and dry groups

Eyes, n (patients, n)

59 (59)

12 (12)

47 (47)

Age, years

(range)

74.3 ± 7.9

(50–88)

77.0 ± 5.9

(66–85)

73.7 ± 8.2

(50–88)

0.19

Sex (M/F), n

41/18

7/5

34/13

0.48^†

Subtype (tAMD/PCV)

30/29

6/6

24/23

1.00^†

Axial length, mm

23.74 ± 0.91

23.61 ± 1.05

23.77 ± 0.89

0.59

LogMAR BCVA

 Baseline

0.28 ± 0.32

0.31 ± 0.37

0.27 ± 0.31

0.69

 1 year after treatment

0.18 ± 0.35

0.21 ± 0.24

0.17 ± 0.38

0.74

 Change during 1 year

− 0.10 ± 0.27

− 0.10 ± 0.27

− 0.10 ± 0.27

0.96

Central retinal thickness at baseline, μm

280.4 ± 113.6

306.8 ± 118.8

273.7 ± 112.5

0.37

Subfoveal choroidal thickness at baseline, μm

231.8 ± 111.3

209.9 ± 90.4

237.4 ± 116.2

0.45

Genotype, n

 ARMS2 A69S (GG/GT/TT)

11/26/20^a

1/6/4^b

10/20/16^c

0.60^‡

 CFH I62V (AA/AG/GG)

6/30/21^d

1/5/5^e

5/25/16^f

0.54^‡

Vitreomacular interface scores at baseline

 25 points

19.5 ± 9.1

23.0 ± 4.3

18.6 ± 9.8

0.03*

 9 points

6.5 ± 3.7

7.6 ± 3.0

6.3 ± 3.8

0.21

 1 point

0.7 ± 0.5

0.8 ± 0.5

0.6 ± 0.5

0.47

Qualitative vitreomacular interface status at baseline (VMA/VMT/complete PVD), n

16/0/43

1/0/11

15/0/32

0.10^‡

Qualitative vitreomacular interface status at baseline (VMA/complete PVD), n

16/43

1/11

15/32

0.10^†